home > epc > autumn 2003 > electronic tools for drug development and registration from a cro's perspective
European Pharmaceutical Contractor

Electronic Tools for Drug Development and Registration from a CRO's Perspective

A medium-sized CRO needs to balance their resources carefully in a rapidly changing legal environment. It is vital to have the tools available to serve the needs of both international and national clients and to fine-tune the range of services.

For the core areas of clinical operations, regulatory affairs and data management, different tools are currently available either as software on a license basis or as a service provided by specialised suppliers.

The actual scope, taking the German scenario into account, is:

e-Trials (electronic data capture, e-trial tracking and e-trial management)
Electronic 'AWB' (drug surveillance)
Electronic common technical document (electronic tools for the eCTD)


Electronic data capture has been discussed in numerous articles and meetings for a considerable period of time. The advantages are numerous, the most important, among others, being:

Rapidly available clinical data drives a trial forward with fast decision-making processes
To change the role of the CRA
To avoid the bottleneck for data management in the data cleaning and query resolution prior to database lock
To encourage investigators to complete the electronic case report form quickly and to ease the process of reporting

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

By Dr Uwe Albrecht, Managing Director of Mediconomics GmbH and Chief Executive Officer of Mediconomics Inc

Dr Uwe W Albrecht started his professional life in 1984 at Behringwerke, Marburg/Lahn where he worked as a CRA on Phase II and Phase III trials in oncology and haematology. By the end of 1987, Dr Albrecht joined Glaxo GmbH, Germany, from which he moved on to Glaxo Group Research Ltd, London, as Senior Clinical Research Scientist in 1990. Moving back to Germany, Dr Albrecht joined Wellcome Germany, mainly focussing on drug development in virology.

In 1993, he was employed at the Institut für Gesundheitsforschung (Institute for Health Research) near Munich as Director of Clinical Research and Regulatory Affairs. From 1995 to 1997, Dr Albrecht worked as Scientific Director with Norgine, Marburg, before joining Pharmakopius International as Head of German Operations. In 1999, he joined Mediconomics GmbH, Hannover as Managing Director.

Dr Uwe Albrecht
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

Unmet Medical Needs? Impacted by unmet Life Sciences Staffing Needs?

Clinical Professionals

Whilst the majority of Clinical Professionals clients are working to discover and develop innovative, cost effective medicines that address unmet medical needs they are not impacting the unmet needs of training and developing new recruits into the pharma industry. The impact is highlighted within entry level Clinical Trial Administrators and Clinical Research Associates (CTA/CRA). In the past the Pharmaceutical industry had highly developed training programs for these sought after candidates. As the use of outsourcing models and CRO’s has increased and fewer Pharma businesses embark on their own R&D a substantial gap is developing in newly trained Life Science graduates entering the market to commence a career within R&D. As further financial cuts are made within R&D spend this already dire situation continues to escalate.
More info >>

Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement